Cargando…

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer

PURPOSE: An oxaliplatin-based regimen is the most common adjuvant chemotherapy for patients with stage II/III colorectal cancer, but many patients experience dose reduction or early termination of chemotherapy due to side effects. We conducted this study to verify the range of reduction with oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Dawon, Baek, Se-Jin, Kwak, Jung-Myun, Kim, Jin, Kim, Seon-Hahn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Surgical Society 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880977/ https://www.ncbi.nlm.nih.gov/pubmed/29629354 http://dx.doi.org/10.4174/astr.2018.94.4.196

Ejemplares similares

Clinical Outcomes of Ileostomy Closure According to Timing During Adjuvant Chemotherapy After Rectal Cancer Surgery
por: Choi, Yoo Jin, et al.
Publicado: (2019)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Clinical characteristics of patients in their forties who underwent surgical resection for colorectal cancer in Korea
por: Lee, Chang Sin, et al.
Publicado: (2021)

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study
por: Le Roy, Bertrand, et al.
Publicado: (2016)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Outcomes according to body mass index following laparoscopic surgery in patients with colorectal cancer
por: Kwak, Han Deok, et al.
Publicado: (2018)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Association between Abdominal Obesity and Incident Colorectal Cancer: A Nationwide Cohort Study in Korea
por: Nam, Ga Eun, et al.
Publicado: (2020)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Early Systemic Failure After Preoperative Chemoradiotherapy for the Treatment of Patients With Rectal Cancer
por: Choi, Taesun, et al.
Publicado: (2019)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

Adjuvant oxaliplatin-based chemotherapy effect after treatment of colorectal hepatic metastasis
por: Kang, Mee-Young, et al.
Publicado: (2021)

Clinical characteristics and oncologic outcomes in patients with preoperative clinical T3 and T4 colon cancer who were staged as pathologic T3
por: Choo, Jeong-Min, et al.
Publicado: (2020)

Bowel function and quality of life after minimally invasive colectomy with D3 lymphadenectomy for right-sided colon adenocarcinoma
por: Lee, Ki-Myung, et al.
Publicado: (2020)

Anus-Preserving Surgery in Advanced Low-Lying Rectal Cancer: A Perspective on Oncological Safety of Intersphincteric Resection
por: Piozzi, Guglielmo Niccolò, et al.
Publicado: (2021)

Characteristics and outcomes of colorectal cancer surgery by age in a tertiary center in Korea: a retrospective review
por: Lee, Tae-Hoon, et al.
Publicado: (2022)

Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report
por: Wang, Danping, et al.
Publicado: (2019)

Anastomotic Sinus That Developed From Leakage After a Rectal Cancer Resection: Should We Wait for Closure of the Stoma Until the Complete Resolution of the Sinus?
por: Chung, Chris Tae-Young, et al.
Publicado: (2019)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

The efficacy of oxaliplatin combination adjuvant chemotherapy for elderly patients with stage III colorectal cancer
por: Hayashi, Naomi, et al.
Publicado: (2020)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
por: Hannan, Liam M, et al.
Publicado: (2012)

Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy
por: Harada, Kazuaki, et al.
Publicado: (2019)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells
por: Tam, Shing-Yau, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r2fcohhod1eg7452s6drs798cb